Azora Therapeutics Inc AZR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $3.71
- Day Range
- $3.91–3.95
- 52-Week Range
- $0.21–7.20
- Bid/Ask
- $3.92 / $3.95
- Shares Outstanding
- 2.63M
- Market Cap
- $10.29M
- Volume/Avg
- 14,003 / 54,488
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
Valuation
Metric | AZR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | AZR |
|---|---|
Quick Ratio | 5.61 |
Current Ratio | 5.63 |
Interest Coverage | — |
Quick Ratio
AZR
Profitability
Metric | AZR |
|---|---|
Return on Assets (Normalized) | −478.45% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AZR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<ZJBqT | LOCK|X^#j$ | $138B | |||
| Moderna Inc MRNA | LOCK|LbK@!hp | LOCK|#F | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|zntq!$y | LOCK|kSwf | $93B | |||
| argenx SE ADR ARGX | LOCK|q#BK<F | LOCK|WLs | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|C%h$J%T | LOCK|FM# | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>M%gzq% | LOCK|P?qb | $30B | |||
| Incyte Corp INCY | LOCK|@?<L?P> | LOCK|k> | $24B | |||
| BioNTech SE ADR BNTX | LOCK|!@$%<M | LOCK|$W | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|p<B^<j& | LOCK|&K!^> | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&Ng?FH^ | LOCK|!w | $15B |
United States